Suchergebnisse - "Luke, David R"

PubPharm (35)

1

Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)

enthalten in: BMJ open | 2024

von Somayaji, R. | Luke, D. | Lau, A. | +16

2

Phase 1 Study of the Pharmacology of BTI320 Before High-Glycemic Meals

enthalten in: Clinical pharmacology in drug development | 2019

von Luke, D. | Lee, K. | Rausch, C. | +1

3

Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment

enthalten in: Journal of clinical pharmacology | 2018

von Hoover, R. | Alcorn, H. | Lawrence, L. | +4

4

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment

enthalten in: The Journal of Clinical Pharmacology | 2018

von Hoover, R. | Alcorn, H. | Lawrence, L. | +4

5

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

enthalten in: Journal of clinical pharmacology | 2017

von Hoover, R. | Marbury, T. | Preston, R. | +5

6

Telavancin hospital-acquired pneumonia trials : impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2015

von Lacy, M. | Stryjewski, M. | Wang, W. | +6

7

Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality

in: Clinical Infectious Diseases | 2015

von Lacy, M. | Stryjewski, M. | Wang, W. | +6

8

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality

enthalten in: Clinical infectious diseases | 2015

von Lacy, M. | Stryjewski, M. | Wang, W. | +6

9

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality

enthalten in: Clinical infectious diseases | 2015

von Lacy, M. | Stryjewski, M. | Wang, W. | +6

10

Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections

enthalten in: Journal of medicinal chemistry | 2013

von Magee, T. | Brown, M. | Starr, J. | +32